An observational study in Upper Tract Urothelial Carcinoma, sponsored by Peking University First Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Peking University First Hospital · Observational
This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.
6,738 studies on the registry are indexed under Carcinoma; 1,159 are open to participants now.
This study's planned enrollment of 200 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Locally advanced UTUC patients such as pathological diagnosed as UTUC with muscle-invasion stages or lymph nodes metastasis.
Exclusion Criteria:
Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Depleted (D, TSR-low\&sTIL-low)
Drug: Chemotherapy
Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Fibrotic (F, TSR-high\&sTIL-low)
Drug: Chemotherapy combined with immunotherapy
Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Immune Enriched, Non-Fibrotic (IE, TSR-low\&sTIL-high)
Drug: Immunotherapy
Participants were classified into four subtypes based on various combinations of TSR and sTIL scores: Immune Enriched and Fibrotic (IE/F, TSR-high\&sTIL-high)
Drug: ADC
Gemicitabin and cisplatin
PD-1/PD-L1
ADC drug like RC48
Chemotherapy combined with immunotherapy
DFS
Disease-free survival include death and recurrence
Time frame: 1 year, 3 years and 5 years
ORR
Response rate
Time frame: 3 month after the start of treatment until the end of treatment
OS
Overall survival
Time frame: 1 year, 3 years and 5 years
AE
adverse effects
Time frame: 1-3 months after starting treatment
No study locations are listed for this record.
Plan to share: Yes — http://ai.yorktal.com
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital